China NT Pharma Advances AI Bone Health Pivot and Secures Liquidity Support After Going-Concern Warning

Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialThe latest update is out from China NT Pharma Group Co., Ltd. ( (HK:1011) ). China NT Pharma has outlined progress on its transition to an AI-driven, light-asset healthcare model and measures to bolster liquidity, following a previously disclosed going-concern disclaimer in its 2024 annual report. The group is moving to complete the acquisition of three target companies that effectively give it control of about 58.11% of Zhejiang Kangyuan Medical Equipment, allowing it to integrate core AI bone health diagnostic products such as an AI X-ray bone density system and portable AI X-ray devices, together with associated patents and software, to deepen its presence in AI-based bone health testing and robotics. Its orthopedic drug agency and orthopedic health product businesses are delivering stable revenue in the treatment segment, while partnerships formed in 2025 with a Chinese state-owned enterprise and a health management company to run a smart health management center and digital health services are expected to provide additional steady income streams from 2026. To address liquidity and going-concern concerns, the group has secured extensions or waivers on most loans for the next 12 months, is negotiating further debt term adjustments, and has obtained commitments from major shareholders for continued financial support through loans, underpinning its strategic transformation and near-term debt service capability. The most recent analyst rating on (HK:1011) stock is a Hold with a HK$0.81 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page. More about China NT Pharma Group Co., Ltd. China NT Pharma Group Co., Ltd. is a Cayman Islands-incorporated pharmaceutical group listed in Hong Kong that has been shifting away from heavy pharmaceutical manufacturing assets since 2020, refocusing on light-asset medical and health business models built around artificial intelligence. Its emerging portfolio centers on AI-powered diagnostic and imaging technologies, particularly in bone health, alongside agency sales of orthopedic drugs, orthopedic health products and digital health management services within the Chinese healthcare market. Average Trading Volume: 309,109 Technical Sentiment Signal: Buy Current Market Cap: HK$546.1M